PTI-1

PTI-1
Legal status
Legal status	CA: Schedule II ; DE: NpSG (Industrial and scientific use only) ; UK: Under Psychoactive Substances Act ;
Identifiers
	IUPAC name N,N-diethyl-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)ethanamine;
CAS Number	1400742-46-2;
ChemSpider	32055537;
UNII	FSE9R26430;
Chemical and physical data
Formula	C21H29N3S
Molar mass	355.54 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCN1C=C(C2=NC(CN(CC)CC)=CS2)C3=CC=CC=C31.Cl;
	InChI InChI=1S/C21H29N3S.ClH/c1-4-7-10-13-24-15-19(18-11-8-9-12-20(18)24)21-22-17(16-25-21)14-23(5-2)6-3;/h8-9,11-12,15-16H,4-7,10,13-14H2,1-3H3;1H; Key:NPYOTZAJIONLKZ-UHFFFAOYSA-N;

PTI-1 is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-2. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4][5]

References

"PTI-1". Cayman Chemical. Retrieved 8 July 2015.
Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004
Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005
Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007
Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic & Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "PTI-1". Cayman Chemical. Retrieved 8 July 2015.

[2] Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004

[3] Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005

[4] Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007

[5] Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic & Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082

PTI-1

See also

References